Modulatory Effect of *Chelidonium majus* Extract and Its Alkaloids on LPS-Stimulated Cytokine Secretion in Human Neutrophils

Sylwia Zielińska 1,* , Monika Ewa Czerwińska 2 , Magdalena Dziagwa-Becker 3 , Andrzej Dryś 4 , Mariusz Kucharski 3 , Anna Jezińska-Domaradzka 1, Bartosz J. Płachno 5 and Adam Matkowski 1,6

1 Department of Pharmaceutical Biology, Wrocław Medical University, Borowska 211, 50-556 Wrocław, Poland; anna.jezińska-domaradzka@umed.wroc.pl (A.J.-D.); pharmaceutical.biology@wp.eu (A.M.)
2 Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland; monika.czerwinska@wum.edu.pl
3 Department of Weed Science and Tillage Systems, Institute of Soil Science and Plant Cultivation State Research Institute, Orzechowa 61, 50-540 Wrocław, Poland; m.dziagwa@iung.wroc.pl (M.D.-B.); m.kucharski@iung.wroc.pl (M.K.)
4 Department of Physical Chemistry, Wrocław Medical University, Borowska 211A, 50-556 Wrocław, Poland; andrzej.drys@umed.wroc.pl
5 Department of Plant Cytology and Embryology, Jagiellonian University, Gronostajowa 9, 30-387 Kraków, Poland; bartosz.plachno@uj.edu.pl
6 Laboratory of Experimental Cultivation, Botanical Garden of Medicinal Plants, Wrocław Medical University, Al. Jana Kochanowskiego 14, 50-556 Wrocław, Poland

* Correspondence: sylwia.zielinska@umed.wroc.pl

Academic Editors: Gianni Sacchetti and Gerold Jerz

Received: 23 December 2019; Accepted: 13 February 2020; Published: 14 February 2020

Abstract: Due to certain differences in terms of molecular structure, isoquinoline alkaloids from *Chelidonium majus* engage in various biological activities. Apart from their well-documented antimicrobial potential, some phenanthridine and protoberberine derivatives as well as *C. majus* extract present with anti-inflammatory and cytotoxic effects. In this study, the LC–MS/MS method was used to determine alkaloids, phenolic acids, carboxylic acids, and hydroxybenzoic acids. We investigated five individually tested alkaloids (coptisine, berberine, chelidonine, chelerythrine, and sanguinarine) as well as *C. majus* root extract for their effect on the secretion of IL-1β, IL-8, and TNF-α in human polymorphonuclear leukocytes (neutrophils). Berberine, chelidonine, and chelerythrine significantly decreased the secretion of TNF-α in a concentration-dependent manner. Sanguinarine was found to be the most potent inhibitor of IL-1β secretion. However, the overproduction of IL-8 and TNF-α and a high cytotoxicity for these compounds were observed. Coptisine was highly cytotoxic and slightly decreased the secretion of the studied cytokines. The extract (1.25–12.5 µg/mL) increased cytokine secretion in a concentration-dependent manner, but an increase in cytotoxicity was also noted. The alkaloids were active at very low concentrations (0.625–2.5 µM), but their potential cytotoxic effects, except for chelidonine and chelerythrine, should not be ignored.

Keywords: isoquinoline alkaloids; cytokine secretion; cytotoxicity; greater celandine

1. Introduction

Isoquinoline alkaloids contained in *Chelidonium majus* L. extracts have been found to be some of the most potent molecules against bacteria, viruses, fungi, and protozoa [1]. This group of compounds is represented mostly by phenanthridine, protoberberine, and protopine derivatives. Roots are richer
in these compounds [2,3], but the European Pharmacopoeia [4] only refers to the alkaloid content of herbs (which should not be less than 0.6% and is calculated in terms of chelidonine content). According to the available literature, roots contain up to 4% alkaloids, while the aerial parts contain 0.1–1% (with the exception of coptisine, which is much more abundant, especially in fruits). Due to differences in their molecular structures, C. majus alkaloids engage in different biological activities [1]. Quaternary nitrogen in molecules, e.g., in chelerythrine, sanguinarine, berberine, or coptisine, has been found to be involved in the inhibition of cellular respiration, whereas the presence of an imine moiety in the structures of sanguinarine and chelerythrine determines the ability of these compounds to inhibit the activity of proteins and enzymes [5].

Abundant data have been gathered since the first experiments on the anti-inflammatory activity of C. majus. Due to the low toxicity of C. majus and its antimicrobial and anti-inflammatory activity, it is recommended for the treatment of oral inflammatory conditions [6]. Over the years, many reports have appeared on the high cytotoxicity of C. majus extracts and individual compounds: these have also pertained to their specific mechanisms of action [7–14].

Apart from structure, which has a decisive impact on the profile and strength of biological activity, the presence of other compounds in plant extracts is also of great importance. In studies independently examining pro- and anti-inflammatory properties, isoquinoline alkaloids have appeared to be effective agents that are highly active even at concentrations 50 times lower than, for instance, polyphenols. In the present study, we examined C. majus root extract and five individual alkaloids for their effects on cytokine secretion in human neutrophils as well as their cytotoxic potential. The phytochemical profile of the C. majus root extract was performed using liquid chromatography with a triple-quadrupole analyzer (LC–MS/MS).

2. Results

2.1. Phytochemical Analysis

In the phytochemical profile of the C. majus root extract, a total of 25 compounds were identified in negative (12 compounds) or positive (13 compounds) electrospray ionization mode. Seven isoquinoline alkaloids—two protopine derivatives (protopine, allocryptopine), two protoberberine derivatives (coptisine, berberine), and three phenanthridine derivatives (chelidonine, sanguinarine, chelerythrine)—as well as unidentified derivatives of protopine (12), chelidonine (18), tetrahydroberberine (21), tetrahydrocoptisine (22), and coptisine (23) were detected (Table 1). The protopine derivative (12) exhibited the most abundant precursor ion at m/z 354, and after disintegration, the product ion at m/z 320.2 corresponded to protopine (25, R1 = 12.76 min). For allocryptopine (13), a parent ion at m/z 369.6 was chosen, as were product ions at m/z 352, 187.95, and 290. The assignment of the chelidonine derivative (18, R1 = 8.84 min) was based on the characteristic loss of a fragment of m/z 353.8, which was attributable to a protonated molecule of chelidonine (19, R1 = 9.56 min). For tetrahydroberberine (21), also known as canadine, the most abundant ion was a precursor ion at m/z 340, while for berberine (16), it was a parent ion at m/z 336.4 and product ions at m/z 320, 292, and 321.1. Coptisine (15) produced a parent ion at m/z 320.1, whereas tetrahydrocoptisine (22) and one other coptisine derivative (23) produced a parent ion at m/z 324. Chelerythrine (20, R1 = 10.44 min) and sanguinarine (24, R1 = 11.80 min) showed parent ions at m/z 348.1 and 332.1, respectively.

A quantitative analysis revealed that no individual compound predominated in the extract, although large differences between alkaloids and compounds from other chemical groups were observed in the contents (Table 1). Next to sanguinarine (1373.80 µg/g), chelerythrine, which was the most abundant (1761.22 µg/g), chelidonine (1181.41 µg/g), and coptisine (1077.06 µg/g) were detected in relatively large proportions (Figure 1). Derivatives of protopine, chelidonine, coptisine, and berberine were also present, but in amounts below LOQ (Table 1). Three nonaromatic carboxylic acids (malic acid (1, dicarboxylic acid), trans-aconitic acid (2, polycarboxylic acid), and quinic acid (3, trans-aconitic acid)
cyclohexanecarboxylic acid)); three hydroxybenzoic acids (salicylic acid (7), protocatechuic acid (4), and vanillic acid (5)); two hydroxycinnamic acids (trans-caffeic acid (6) and p-coumaric acid (9)); one caffeic acid ester (rosmarinic acid (10)); one flavonoid (quercetin (17)); one phenolic aldehyde (vanillin (11)); and one quinine sulfate (14) were detected in the root extract.

Table 1. Mass spectrometric conditions and contents of the detected compounds, their retention times (Rt), and their molecular ([M – H]+) and fragment ions in negative and positive mode in Chelidonium majus root extract.

| No | Compound                  | Retention Time (min) | Parent Ion (m/z) | Product Ion (m/z) | Ion Mode | Content (µg/g) |
|----|---------------------------|----------------------|------------------|-------------------|----------|----------------|
| 1. | malic acid                | 1.08                 | 133.1            | 115.71            | –        | p              |
| 2. | trans-aconitic acid       | 1.15                 | 172.9            | 85, 129           | –        | p              |
| 3. | quinic acid               | 1.3                  | 191              | 85, 93            | –        | p              |
| 4. | protocatechuic acid       | 1.54                 | 153              | 109, 108          | –        | LOQ            |
| 5. | vanillic acid             | 2.37                 | 167.3            | 151.9, 107.9      | –        | LOD            |
| 6. | trans-caffeic acid        | 2.71                 | 179.2            | 135, 134, 89      | –        | p              |
| 7. | salicylic acid            | 2.79                 | 137.3            | 93, 65.05, 44.8   | –        | LOD            |
| 8. | hydroxybenzoic acid       | 2.85                 | 137.3            | 93                | –        | LOQ            |
| 9. | p-coumaric acid           | 3.97                 | 163.2            | 119.1, 93.1, 117  | –        | p              |
| 10.| rosmarinic acid           | 4.98                 | 399.1            | 161, 197.15       | –        | LOD            |
| 11.| vanillin                  | 5.15                 | 151.2            | 136, 91.85, 108   | –        | p              |
| 12.| protopine derivative      | 6.75                 | 354              | 320, 260, 196     | +        | p              |
| 13.| allocryptopine            | 6.80                 | 369.6            | 352, 187.95, 290  | +        | 98.94 ± 0.02   |
| 14.| quinine sulfate           | 7.00                 | 747.4            | 325.1             | +        | p              |
| 15.| coptisine                 | 7.50                 | 320.1            | 291.95, 204.05, 262.05 | + | 1077.06 ± 26.24 |
| 16.| berberine                 | 7.95                 | 336.4            | 320, 292, 321.1   | +        | 722.62 ± 19.25 |
| 17.| quercetin                 | 8.34                 | 301.1            | 151.05, 65.121    | –        | LOD            |
| 18.| chelidonine derivative    | 8.84                 | 370              | 356, 339          | +        | p              |
| 19.| chelidonine               | 9.56                 | 353.8            | 275, 189, 247     | +        | 1181.41 ± 72.78 |
| 20.| chelerythrine             | 10.44                | 348.1            | 332, 304, 333     | +        | 1761.22 ± 33.80 |
| 21.| tetrahydroberberine       | 10.55                | 340              | 176, 149          | +        | p              |
| 22.| tetrahydrodrcoptisine     | 11.10                | 324              | 176, 149          | +        | p              |
| 23.| coptisine derivative      | 11.20                | 324              | 190               | +        | p              |
| 24.| sanguinarine              | 11.80                | 332.1            | 274.1, 316.95, 246 | + | 1373.80 ± 27.50 |
| 25.| protopine                 | 12.76                | 320.2            | 303.2, 107, 123.85 | +        | p              |

Here, p—present, where identification was based on mass spectra with no reference substances; LOD—limit of detection; LOQ—limit of quantification.

Figure 1. Multiple reaction monitoring (MRM) chromatogram of alkaloids in the crude acidified MeOH extract of C. majus roots.
2.2. Bioactivity Assays

Berberine, chelidonine, and chelerythrine decreased the secretion of TNF-α in human neutrophils in a concentration-dependent manner. The cells treated with chelidonine and chelerythrine at concentrations of 0.625 µM released 46.4% ± 12.4% and 83.1% ± 10.5% of TNF-α, respectively, compared to (+) LPS-treated cells (100% ± 9.8%). It is worth noting that neither chelidonine nor chelerythrine were toxic in this cell model (Figure 2). Only berberine at the highest concentration of 2.5 µM significantly increased the number of dead cells. However, berberine at a concentration of 0.625 µM inhibited TNF-α (secretion of 60.1% ± 11.4% compared to (+) LPS, which was 100% ± 9.8%), and it was not toxic at this concentration.

Sanguinarine was the most potent inhibitor of IL-1β secretion. However, the overproduction of IL-8 and TNF-α was observed at lower concentrations (Figure 3B, Figure 4B, Figure 5B, and Figure 6A–D). This compound, at 2.5 µM, significantly inhibited both IL-8 and TNF-α release (by neutrophils) compared to other concentration levels, but it was also highly cytotoxic. However, the secretion of IL-1β by cells treated with sanguinarine at a concentration of 0.625 µM, which was not cytotoxic, was reduced to 52.2% ± 3.1% compared to the negative control LPS-stimulated cells.
Figure 3. The effect of root extract (A: 1.25–12.5 μg/mL) and alkaloids (B: 0.625–2.5 μM) on neutrophil IL-1β release by LPS-stimulated (100 ng/mL) cells ((+) LPS). Dex-dexamethasone at concentrations of 0.25, 0.5, and 1.0 μM. The data are expressed as the mean ± SE from three donors assayed in triplicate. The statistical significance of the compounds and extract versus the stimulated control at $p < 0.05$ is marked by two different letters: a and b (ANOVA followed by a Kruskal–Wallis test).

Coptisine slightly decreased the secretion of cytokines tested in this study, but it was highly cytotoxic in a concentration range of 0.625–2.5 μM (Figures 2B, 3B, 4B, 5B and 6A–D).

*C. majus* root extract induced the secretion of all cytokines in a dose-dependent manner in a concentration range from 1.25 μg/mL to 12.5 μg/mL (Figure 3A, Figure 4A, Figure 5A). It was highly cytotoxic at concentrations of 6.25 and 12.5 μg/mL (Figure 2A) as well as at a higher concentration range of 25–100 μg/mL (data not shown). It is worth noting that the extract, at a concentration of 1.25 μg/mL, did not exert any cytotoxic effects compared to nontreated cells (Figure 2A), but its influence on cytokine release was insignificant (Figure 3A, Figure 4A, Figure 5A).
Figure 4. The effect of root extract (A: 1.25–12.5 μg/mL) and alkaloids (B: 0.625–2.5 μM) on neutrophil IL-8 release by LPS-stimulated (100 ng/mL) cells ((+LPS). Dex-dexamethasone at concentrations of 0.25, 0.5, and 1.0 μM. The data are expressed as the mean ± SE from three donors assayed in triplicate. The statistical significance of the compounds and extract versus the stimulated control at \( p < 0.05 \) is marked by two different letters: a and b (ANOVA followed by a Kruskal–Wallis test).
Figure 5. The effect of root extract (A: 1.25–12.5 μg/mL) and alkaloids (B: 0.625–2.5 μM) on neutrophil TNF-α release by LPS-stimulated (100 ng/mL) cells ((+) LPS). Dex-dexamethasone at concentrations of 0.25, 0.5, and 1.0 μM. The data are expressed as the mean ± SE from three donors assayed in triplicate. The statistical significance of the compounds and extract versus the stimulated control at p < 0.05 is marked by two different letters: a and b (ANOVA followed by a Kruskal–Wallis test).
Figure 5. The effect of root extract (A: 1.25–12.5 μg/mL) and alkaloids (B: 0.625–2.5 μM) on neutrophil TNF-α release by LPS-stimulated (100 ng/mL) cells ((+) LPS). Dex-dexamethasone at concentrations of 0.25, 0.5, and 1.0 μM. The data are expressed as the mean ± SE from three donors assayed in triplicate. The statistical significance of the compounds and extract versus the stimulated control at p < 0.05 is marked by two different letters: a and b (ANOVA followed by a Kruskal–Wallis test).

Figure 6. The results of a two-way ANOVA by type and concentration of the alkaloid in terms of the secretion of three cytokines (A–C) and cytotoxicity (D). The data are expressed as mean values ± the SE of two separate experiments. Cells were isolated from three independent donors and assayed in triplicate.

3. Discussion

The extract from the C. majus roots collected for this study (in early spring (9th of April)) was rich in chelerythrine, sanguinarine, chelidonine, and coptisine (Table 1), without the significant predominance of any of these alkaloids. Sanguinarine was not the most abundant compound, as has been previously reported for roots harvested later in the vegetation season (end of May and June) [3] and in autumn (data not published). Coptisine has been previously found to be the most abundant alkaloid in the aerial parts of plants, particularly in fruits [3]. However, the roots are rather poor in this alkaloid. Additionally, a much larger amount of berberine in root extract was found in the current study, whereas the compound was nearly absent in both aerial and underground parts collected later in the vegetation season, as well as in organ and tissue in vitro cultures [2,3]. Not much is known about isoquinoline alkaloid conversion along the biosynthesis pathway. A biosynthetic pathway for different classes of isoquinoline alkaloids has been proposed for Coptis japonica (Thunb.) Makino and Papaver somniferum L [15]. The authors examined the production stability of benzylisoquinoline alkaloids in C. japonica-transformed plants for 4 and 20 months. Chromatographic analyses revealed that plants cultivated for a longer period accumulated alkaloids at higher levels [15]. The mechanisms involved in alkaloid transport across the tonoplast are also not very well understood. Berberine is one of the best known isoquinoline alkaloids in this respect. A suggested model for berberine transport and accumulation in the vacuoles of Coptis japonica cells has been presented by Otani et al. [16]. In an intact tonoplast and vacuole vesicle system, berberine uptake was stimulated by Mg/pyrophosphate, Mg/adenosine triphosphate (ATP), guanosine-5′-triphosphate (GTP), cytidine triphosphate (CTP), and uridine-5′-triphosphate (UTP). On the other hand, ammonium cation and bafilomycin A1 strongly inhibited berberine uptake, whereas vanadate, which is used to inhibit ATP-binding cassette transporters, presented only a slight effect, which suggested the occurrence of a typical secondary transport mechanism [16].

The share of individual alkaloids in latex composition influences the biological activity profile of raw materials. In the present study, coptisine and sanguinarine were found to be responsible for the highest cytotoxicity, and they were produced in relatively high proportions in roots (1077.06 and
The qualitative analysis revealed that phenolic acids, hydroxybenzoic acids, carboxylic acids, flavonoids, and several of their derivatives were present in the root extract, in addition to alkaloids (Table 1). These components of C. majus root extract may have an important impact on its bioactivity profile (Figures 2–6). Even though the inhibitory activity of cytokine secretion by selected alkaloids has been observed, the relevant activity of the root extract has not been noted. Therefore, compounds other than the alkaloids detected in the extract are likely to attenuate the inhibitory effect of alkaloids in human neutrophils. Phenolic compounds, as well as some other constituents, have been previously detected in the roots and aerial parts of this species [24–28], and research on the anti-inflammatory activity of C. majus constituents, which may cause the inhibition of both infectious and noninfectious inflammation related to chronic inflammatory diseases, seems to be justified. Neutrophils constitute the first line of defense against pathogens, due to their ability to generate oxidative bursts and release antimicrobial substances. Lipopolysaccharide, a component of the outer membranes of Gram-negative bacteria, elicits a cytokine-mediated innate immune response, and therefore it was used as a cell stimulator in our study [23].

The qualitative analysis revealed that phenolic acids, hydroxybenzoic acids, carboxylic acids, flavonoids, and several of their derivatives were present in the root extract, in addition to alkaloids (Table 1). These components of C. majus root extract may have an important impact on its bioactivity profile (Figure 2, Table 1), which could explain a similar effect in the tested root extract. Sanguinarine and C. majus root extract have previously been found to present with cytotoxic and proapoptotic activity in studies on several cell lines obtained from patients with various types of leukemia [7]. In the same study, a similar effect was also shown by berberine, but it was much weaker than sanguinarine. The authors tested only these two alkaloids, and thus their interpretation of the extract’s effects was limited to these substances. In our experiments, chelidonine and chelerythrine proved to be the least cytotoxic (Figures 2 and 6). A previously tested chelidone-rich extract also showed similarly weak cytotoxic effect in vitro studies on HepG2 cells treated with extracts prepared using different solvents. In turn, extracts containing higher amounts of coptisine and sanguinarine showed much stronger properties of this type [17]. To date, other experiments have shown that mitochondrial toxicity is associated with the ability of chelerythrine and sanguinarine to intercalate DNA [18]. Due to the cholangenic and hepatoprotective activities of C. majus, the main applications for this plant pertain to biliary tract and liver disorders, something recently reviewed by Zielińska et al. [1]. Nonetheless, existing clinical evidence is not sufficient to recommend extracts of the herb for usage (European Medicines Agency, 2011) [19]. In previous studies on its mechanisms of action, chelidonine was found to present with cytostatic activity, whereas berberine (16), chelerythrine, and sanguinarine presented with DNA-intercalating abilities, thereby interfering with cell division and replication [10,11,13,14,20]. It is worth noting that the application of Chelidonium-derived products in the treatment of cancer has also been suggested [21]. On the other hand, Chelidonii herba has been traditionally used in the treatment of gastrointestinal disorders, including gall bladder dysfunctions, as a choleretic and cholangue agent [1]. Its traditional use has been cited in studies on acute cholestatic hepatitis [22]. Thus, researching the anti-inflammatory activity of C. majus constituents, which may cause the inhibition of both infectious and noninfectious inflammation related to chronic inflammatory diseases, seems to be justified. Neutrophils constitute the first line of defense against pathogens, due to their ability to generate oxidative bursts and release antimicrobial substances. Lipopolysaccharide, a component of the outer membranes of Gram-negative bacteria, elicits a cytokine-mediated innate immune response, and therefore it was used as a cell stimulator in our study [23].

Alkaloids found in C. majus root extract represent three classes—protopine derivatives, protoberberine derivatives, and phenanthridine derivatives—although in this case, the phenanthrene skeleton as well as the presence of quaternary nitrogen atoms was less important. Both chelerythrine and sanguinarine, as well as berberine and coptisine, contain quaternary nitrogen in their structure, and yet these compounds present with different bioactivity effects, which was also shown in our current study. Similarly, the phenanthrene skeleton present in the structure of chelidonine, chelerythrine, ...
and sanguinarine did not make these three compounds act similarly in terms of cytokine secretion. In previous studies by other researchers, the phenanthrene skeleton had no significant impact on oxygen uptake at the cellular level, whereas other building elements, such as the charge of the molecule, were crucial [5].

Despite the similar effects observed on TNF-α secretion and the relatively low cytotoxicity, berberine, chelidonine, and chelerythrine affected IL-1β and IL-8 secretion differently. The strongest TNF-α inhibition was observed in the case of nontoxic chelidonine. On the other hand, the significant inhibition of IL-8 and TNF-α secretion by sanguinarine at a concentration of 2.5 μM was probably caused by increased toxicity at this concentration. In addition, sanguinarine significantly inhibited IL-1β release by PMNs, even at a nontoxic concentration. The complex role of cytokines in the inflammatory pathways should be underlined. Firstly, the results of the study pointed to multiple mechanisms that may be engaged in the release of interleukin-1β within the same population of cells. The mechanisms of IL-1β secretion depend on factors such as the cell microenvironment, temperature, pH, and osmolarity. These conditions change when inflammatory processes escalate and more mechanisms are involved. In addition, more and more endogenous molecules that are released from dead cells, such as danger-associated molecular patterns (DAMPs), can appear in a changing cell microenvironment, leading to the depletion of the inflammatory response. Therefore, the close relationship between cytotoxic effects and cytokine secretion might explain the different results in terms of the inhibition of cytokine secretion when the cells were treated with alkaloids [31]. However, it should also be noted that even though DAMPs were generated, the isoquinoline alkaloids were able to limit noninfectious inflammation and reduce the cell-to-cell spreading of inflammation. A second important issue is that the major role of cytokines such as IL-8 can be seen as an induction of the chemotaxis of granulocytes in response to infection or tissue injury. IL-8 can stimulate the resolution of infection through the induction of phagocytosis and oxidative burst or the induction of cell proliferation and activation of an angiogenic response. Interleukin-8 expression has been recognized in numerous cancer types. Tumor-derived IL-8 suppresses antitumor immunity through neutrophil recruitment. Thus, the concomitant IL-8 inhibitory effect and the toxicity of some of the tested alkaloids, such as sanguinarine, may reflect potential antitumor effects [32].

4. Material and Methods

4.1. Plant Material

*Chelidonium majus* L. root and root collars were collected on 9 April 2019 in Poland (Wroclaw, Okólna Street, 51°06′02.0″ N 17°03′34.0″ E51.100545, 17.059446). Dried raw material (70 g) was powdered using mortar and pestle. The extracts were prepared in round-bottom flasks in an ultrasonic bath (2 × 2 h), with a solvent-to-solid ratio of 1:20 (v/w). Methanol and 50 mM hydrochloric acid were used for sample extraction, in accordance with procedures used in previous studies [33,34].

4.2. Phytochemical Analysis

The identification and quantification of the *C. majus* extract was performed using liquid chromatography–electrospray ionization–tandem mass spectrometry (LC–ESI–MS/MS) (Shimadzu, Kyoto, Japan).

4.2.1. Reagents and Reference Substances

Water, LC–MS-grade methanol, and eluent-additive LC–MS ultra-ammonium formate (NH₄HCO₃) were purchased from Fluka Analytical (St. Louis, MO, USA).

Alkaloid standards such as chelidonine (purity ≥ 95%), sanguinarine (purity ≥ 90%), chelerythrine (purity ≥ 90%), and berberine (purity ≥ 95%) were purchased from Extrasynthese (France). Coptisine (purity ≥ 98%), p-coumaric acid, tannic acid, salicylic acid, chlorogenic acid, vanillic acid, *trans*-caffeic
acid, vanillin, rosmarinic acid, quinine sulfate, and quercetin were purchased from Sigma (St. Louis, MO, USA).

Water was deionized and purified by ULTRAPURE Millipore Direct-QVR 3UV-R (Merck, Darmstadt, Germany).

4.2.2. Liquid Chromatography

A liquid chromatography (LC) analysis was carried out with the use of a Shimadzu Prominence UFLC system (Shimadzu, Kyoto, Japan). It was equipped with a binary solvent manager (LC-30 ADXR), a degasser (DGU-20A3), a column oven (CTO-10ASVP), an autosampler (SIL 20AXR), and a system controller (CBM-20A), and it was interfaced to a triple-quadrupole analyzer. The chromatographic separation was performed using a Kinetex column (C18, 2.6 µm, 100 × 3.0 mm, Phenomenex, Torrance, CA, USA). The column temperature was maintained at 35 °C. The mobile phase was prepared as a mixture (A, B) consisting of 10 mM ammonium formate in water (A) and 0.1% formic acid in methanol (B). The methanol percentage was changed linearly: 0 min, 10%; 10 min, 85%; 13.01 min, 85%; 16 min, 10%. A sample volume of 10 µL was injected into the UHPLC system.

4.2.3. Mass Spectrometry

The analysis was performed using a triple-quadrupole tandem mass spectrometer (LCMS-8030, Shimadzu, Kyoto, Japan) with ultrafast polarity switching and ultrafast multiple reaction monitoring (MRM) transitions. Nebulizing gas (obtained from pressurized air in an N2 LC–MS pump) and nitrogen were dried, working at a flow rate of 3 L/min and 15 L/min, respectively. The desolvation line temperature and the heat block temperature were 250 °C and 400 °C, respectively. Argon 99% (Linde, Wroclaw, Poland) was used as a collision-induced dissociation gas (CID) at a pressure of 230 kPa. A dwell time of 10 ms was selected. To process the quantitative data, LabSolution Ver. 5.6 (Shimadzu, Kyoto, Japan) software was used.

4.2.4. Identification and Quantification

A full scan as well as MS/MS spectra were obtained during flow injection analysis (FIA) of each standard. For the identification and quantification of analytes, multiple reaction monitoring (MRM) mode was used. For most of the compounds, at least two transitions were chosen: the first one for quantitative purposes (Q) and the second one as confirmation (q). This was accomplished with a retention time and ion intensity ratio compared to corresponding reference substances and compounds (reported previously) [2].

The limit of detection (LOD) was calculated according to a signal-to-noise ratio (S/N) of 3, and the limit of quantitation (LOQ) was calculated according to an S/N ratio of 10. Linearity was evaluated from the square correlation coefficients (r²) of the regression curves obtained for each standard, and r² ≥ 0.99 was achieved for all compounds. The changes in retention time, expressed as relative standard deviation, were not significant. The RSD% for the retention time never exceeded 2.5%.

4.3. Bioactivity Assays

4.3.1. Chemicals

L-glutamine, HEPES buffer solution, fetal bovine serum (FBS), and RPMI 1640 medium were purchased from Sigma-Aldrich (St. Louis, MO, USA). Lipopolysaccharide (LPS from Escherichia coli 0111:B4) was purchased from Merck. Human ELISA sets (interleukin 1 beta (IL-1β), interleukin 8 (IL-8), tumor necrosis factor alpha (TNF-α), and propidium iodide (PI)) were purchased from BD Biosciences (New Jersey, U.S.). Phosphate-buffered saline (PBS) was obtained from Gibco. Penicillin and streptomycin were purchased from PAA (Cölbe, Germany). The water used in the study was purified using a water purification system (MILLIPORE Simfilter Simplicity UV, Merck, Darmstadt, Germany).
4.3.2. Neutrophil Polymorphonuclear Granulocyte (PMN) Isolation

Buffy coats were obtained from the Warsaw Blood Donation Center (Warsaw, Poland). Donors of the blood (<35 years old) were diagnosed as healthy, according to their medical history and a routine laboratory test. Donors declared that they were not taking medication and that they were nonsmokers. Their good health condition was clinically confirmed, and a routine laboratory test revealed values within a normal range. Polymorphonuclear neutrophils (PMNs) were isolated using dextran sedimentation and centrifugation in a Ficoll Hypaque gradient (1500 rpm, 4 °C). Hypotonic lysis was performed to remove erythrocytes. The obtained cells were suspended in an RPMI 1640 medium [35].

4.3.3. Cytotoxicity

Neutrophil cytotoxicity was assessed by flow cytometry with PI staining. The *C. majus* root extract was studied in a concentration range from 1.25 to 12.5 µg/mL, whereas the compounds were tested at concentrations of 0.625 µM, 1.25 µM, and 2.5 µM. After 20 h, the neutrophils (2 × 10⁶/mL in RPMI 1640 medium) were incubated with the tested *C. majus* root extract and the test compounds. Cell centrifugation was performed at 2000 rpm for 10 min at 4 °C. Neutrophils were rinsed twice with PBS, resuspended in PBS (500 µL) containing 5 µL of PI (50 µg/mL), and then left for 15 min in the dark. The cells were analyzed using flow cytometry with a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA), and the data was recorded (10,000 events). These cells, which displayed high permeability to propidium iodide, were expressed as a percentage of PI (+) cells. As a positive control, TritonX was used. The results of the viability were calculated according to an equation: 100% − PI (+) cells%.

4.3.4. IL-8, TNF-α, and IL-1β Production by PMNs

PMNs (2 × 10⁶/mL) were maintained in 96-well plates in RPMI 1640 medium and with 10% FBS, 2 mM L-glutamine, 10 mM HEPES, and penicillin and streptomycin (1%, v/v) for 20 h at 37 °C with 5% CO₂, and in the absence or presence of the tested compounds. The compounds were added 30 min before stimulation with lipopolysaccharide (100 ng/mL; LPS). The *C. majus* root extract was studied in a concentration range from 1.25 to 12.5 µg/mL, whereas the compounds were tested at concentrations of 0.625 µM, 1.25 µM, and 2.5 µM. Dexamethasone (Dex) was used as a positive control. The TNF-α, IL-8, and IL-1β released into cell supernatants were measured using an enzyme-linked immunosorbent assay (ELISA) according to the instructions of the manufacturer. The effect on IL-8, TNF-α, and IL-1β production was calculated as a percentage of the released agent compared to the stimulated control (+) LPS (without the extract being tested).

4.4. Statistical Evaluations

Statistical significance showing differences between means was established using an ANOVA followed by a Brown–Forsythe test. Here, p-values below 0.05 were considered statistically significant. The results are expressed as the mean ± SE. The first step was to check which values were considered to be outliers by the statistical program. Then, the normality of the distribution was checked, and an analysis of variance was used. Additionally, a Kruskal–Wallis test (nonparametric) was performed. To examine the influence of the type of alkaloid and the alkaloid concentration on cytokine secretion or cytotoxicity, a two-way ANOVA was performed (Figure 6A–D). All analyses were conducted using Statistica ver. 10 (StatSoft, Cracow, Poland).

5. Conclusions

*C. majus* extract and its alkaloids exhibited strong modulatory effects on the three cytokines secreted. The results of our research indicate that coptisine and sanguinarine had the largest effect in terms of the mechanisms associated with the development of a cytotoxic effect in LPS-stimulated human neutrophils. On the other hand, sanguinarine was found to be one of the most potent inhibitors
of IL-1β secretion, which was not reflected in the activity of the plant extract. Isoquinolone alkaloids were also found to be active at very low concentrations. In further experiments with selected substances based on the results obtained in the current study, the range of concentrations of the tested substances will have to be expanded in order to determine the threshold concentration at which a cytotoxic effect is observed. Moreover, future experiments based on testing mixtures of selected alkaloids in various proportions relative to each other would allow us to explore mechanisms of possible synergy (the addition or abolition of biological effects).

Author Contributions: Conceptualization, S.Z.; methodology, S.Z., M.E.C., and M.K.; data curation, S.Z., M.E.C., and M.D.-B.; software, S.Z., M.E.C., and M.D.-B.; validation, M.D.-B. and A.D.; formal analysis, S.Z., M.E.C., and M.D.-B.; investigation, S.Z. and M.E.C.; resources, A.M., M.E.C., and M.K.; writing—original draft preparation, S.Z. and M.E.C.; writing—review and editing, S.Z., M.E.C., A.M., and M.D.-B.; visualization, S.Z., M.E.C., A.J.-D., and B.J.P.; supervision, M.E.C. and A.M.; project administration, S.Z.; funding acquisition, A.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Wroclaw Medical University project SUB.D033.I9.009, and Ministry of Science and Higher Education (MNiSW), Republic of Poland, Decision No. 96/E394/SPUB/SP/2019.

Acknowledgments: This study was partly supported by the Wroclaw Medical University Foundation (Fundacja Uniwersytetu Medycznego we Wrocławiu, FUM). The Botanical Garden of Medicinal Plants receives support for its special research facility from the Ministry of Science and Higher Education (MNiSW), Republic of Poland, Decision No. 96/E394/SPUB/SP/2019. The project was carried out with the use of CePT infrastructure financed by the European Regional Development Fund within the Operational Programme “Innovative Economy” for 2007–2013. The authors also thank Danuta Raj from the Department of Pharmacognosy and Herbal Medicines for collecting part of the plant material and Hanna Zielinska for her assistance in graphical abstract preparation.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. Zielińska, S.; Jezierska-Domaradzka, A.; Wójciak-Kosior, M.; Sowa, I.; Junka, A.; Matkowski, A.M. Greater Celandine's ups and downs—21 centuries of medicinal uses of Chelidonium majus from the viewpoint of today’s pharmacology. Front. Pharm. 2018, 9, 1–29. [CrossRef] [PubMed]
2. Zielińska, S.; Wójciak-Kosior, M.; Plachno, B.J.; Sowa, I.; Włodarczyk, M.; Matkowski, A. Quaternary alkaloids in Chelidonium majus in vitro cultures. Ind. Crop. Prod. 2018, 123, 17–24. [CrossRef]
3. Zielińska, S.; Wójciak-Kosior, M.; Dąbińska-Dziagwa-Becker, M.; Gierląszk, M.; Sowa, I.; Fijalkowski, K.; Rurańska-Smutnicka, D.; Matkowski, A.; Junka, A. The Activity of Isoquinoline Alkaloids and Extracts from Chelidonium majus against Pathogenic Bacteria and Candida sp. Toxins 2019, 11, 406. [CrossRef]
4. European Pharmacopoeia 9th Edition 2019, 9.7, Greater Celandine, Version Date 07/02/2012, Monographhy Number 1861. European Directorate for the Quality of Medicines and Healthcare, Strasbourg, France. Available online: online6.edqm.eu/ep907/ (accessed on 1 January 2019).
5. Barreto, M.C.; Pinto, R.E.; Arrabaça, J.D.; Pavaó, M.L. Inhibition of mouse liver respiration by Chelidonium majus isquinoline alkaloids. Toxicol. Lett. 2003, 146, 37–47. [CrossRef] [PubMed]
6. Lenfeld, J.M.; Kroutil, E.; Marálek, J.; Slavík, V.; Preininger, V.; Simánek, V. Antiinflammatory Activity of Quaternary Benzopenanthridine Alkaloids from Chelidonium majus. Planta Med. 1981, 43, 161–165. [CrossRef] [PubMed]
7. Och, A.; Żalewski, D.; Komsta, L.; Koldziej, P.; Kocki, J.; Bogucka-Kocka, A. Cytotoxic and Proapoptotic Activity of Sanguinarine, Berberine, and Extracts of Chelidonium majus L. and Berberis thunbergii DC. toward Hematopoietic Tumor Cell Lines. Toxins 2019, 11, 485. [CrossRef]
8. Och, A.; Szewczyk, K.; Pecio, Ł.; Stochmal, A.; Żaluski, D.; Bogucka-Kocka, A. UPLC-MS/MS Profile of alkaloids with cytotoxic properties of selected medicinal plants of the Berberidaceae and Papaveraceae families. Oxid. Med. Cell. Longev. 2017. [CrossRef]
9. Croaker, A.; King, G.J.; Pyne, J.H.; Anoopkumar-Dukie, S.; Simanek, V.; Liu, L. Carcinogenic potential of sanguinarine, a phytochemical used in ‘therapeutic’ black salve and mouthwash. Mutat. Res. Rev. Mutat. Res. 2017, 774, 46–56. [CrossRef]
10. Philchenkov, A.; Kaminskyy, V.; Zavelevich, M.; Stoika, R. Apoptogenic activity of two benzophenanthridine alkaloids from Chelidonium majus L. does not correlate with their DNA damaging effects. *Toxicol. In Vitro* 2008, 22, 287–295. [CrossRef]

11. Basu, P.; Bhowmik, D.; Suresh Kumar, G. The benzophenanthridine alkaloid chelerythrine binds to DNA by intercalation: Photophysical aspects and thermodynamic results of iminium versus alkanolamine interaction. *J. Photoch. Photobiol. B Biol.* 2013, 129, 57–68. [CrossRef]

12. Noureini, S.K.; Wink, M. Transcriptional down regulation of hTERT and senescence induction in HepG2 cells by chelidone. *World J. Gastroenterol.* 2009, 15, 3603–3610. [CrossRef] [PubMed]

13. Panzer, A.; Joubert, A.M.; Bianchi, P.C.; Seegers, J.C. The antimitotic effects of Ukrain R (TM), a Chelidonium majus alkaloid derivative, are reversible in vitro. *Cancer Lett.* 2001, 150, 85–92. [CrossRef]

14. Havelek, R.; Seifrtova, M.; Kralovec, K.; Habartova, K.; Cahlíkova, L.; Rezacova, M. Chelidonine and homochelidonine induce cell death through cell cycle checkpoints and MAP kinase pathways. *Nat. Prod. Commun.* 2016, 12, 1419–1430. [CrossRef]

15. Inui, T.; Kawano, N.; Shitan, N.; Yazaki, K.; Kiuchi, F.; Kawahara, N.; Sato, F.; Yoshimatsu, K. Improvement of benzylisoquinoline alkaloid productivity by overexpression of 3’-hydroxy-N-methylcoclaurine 4’-O-methyltransferase in transgenic Coptis japonica plants. *Biol. Pharm. Bull.* 2012, 35, 650–659. [CrossRef] [PubMed]

16. Otani, M.; Shitan, N.; Sakai, K.; Martinoa, E.; Sato, F.; Yazaki, K. Characterization of vacuolar transport of the endogenous alkaloid berberine in Coptis japonica. *Plant Physiol.* 2005, 138, 1939–1946. [CrossRef]

17. Orland, A.; Knapp, K.; König, G.M.; Ulrich-Merzenich, G.; Knöß, W. Combining metabolomic analysis and microarray gene expression analysis in the characterization of the medicinal plant Chelidonium majus L. *Phytomedicine* 2014, 21, 1587–1596. [CrossRef]

18. Pantano, F.; Mannocchi, G.; Marinelli, E.; Gentili, S.; Graziano, S.; Busardò, F.P.; Di Luca, N.M. Hepatotoxicity induced by Greater celandine (Chelidonium majus L.): A review of the literature. *Eur. Rev. Med. Pharmacol. Sci.* 2017, 21, 46–52.

19. ESCOP 2003, EMA Final Assessment Report. 13 September 2011 EMA/HMPC/369801/2009 Committee on Herbal Medicinal Products (HMPC). Available online: https://pdfs.semanticscholar.org/1aaf/394d1e480e9f342a307397644e7eb946c7ca.pdf. (accessed on 13 September 2011).

20. Noureini, S.K.; Esmaeili, H.; Abachi, F.; Khiali, S.; Islam, B.; Kuta, M. Selectivity of major isoquinoline alkaloids from Chelidonium majus towards telomeric G-quadruplex: A study using a transition-FRET (t-FRET) assay. *Biochim. Biophys. Acta* 2017, 1861, 2020–2030. [CrossRef]

21. Ernst, E.; Schmidt, K. Ukraine—a new cancer cure? A systematic review of randomised clinical trials. *BCM Cancer* 2005, 5, 69. [CrossRef]

22. Moro, P.A.; Cassetti, F.; Giugliano, G.; Falce, M.T.; Mazzanti, G.; Menntiti-Ippolito, F.; Raschetti, R.; Santuccio, C. Hepatitis from Greater celandine (Chelidonium majus L.): Review of literature and report of a new case. *J. Ethnopharmacol.* 2009, 124, 328–332. [CrossRef]

23. Raetz, C.R.H.; Whitfield, C. Lipopolysaccharide endotoxins. *Annu. Rev. Biochem.* 2002, 71, 635–700. [CrossRef] [PubMed]

24. Kopytko, Y.F.; Dargaeva, T.D.; Sokolskaya, T.A.; Grodnitskaya, E.I.; Kopnin, A.A. New methods for the quality control of a homeopathic matrix tincture of greater celandine. *Pharm. Chem. J.* 2005, 39, 603–609. [CrossRef]

25. Deng, A.J.; Zhang, Z.H.; Li, Q.; Ma, L.; Qin, H.L. Two new hopanetype triterpenes from the aerial part of Chelidonium majus. *Phytochem. Lett.* 2016, 17, 75–78. [CrossRef]

26. Kwasniewski, V. Untersuchungen über die nichtalkaloidschen Inhaltstofoxide des Schöllkrauts (Chelidonium majus L.). *Pharmazie* 1958, 13, 3363–3364.

27. Hansel, R.; Keller, K.; Rimpler, H.; Schneider, G. *Hangers Handbuch der Pharmazeutischen Praxis*; Springer: Berlin/Heilderberg, Germany, 1992.

28. Hahn, R.; Nahrstedt, A. Hydroxycinnamic acid derivatives, caffeoylmalic and new caffeylaladonic acid esters, from Chelidonium majus. *Planta Med.* 1993, 59, 71–75. [CrossRef]

29. Granica, S.; Piwowarski, J.P.; Randazzo, A.; Schneider, P.; Żyżyńska-Granica, B.; Zidorn, C. Novel stilbenoids, including cannabinapiradienone glycosides, from Tragopogon tomasinii (Asteraceae, Cichorieae) and their potential anti-inflammatory activity. *Phytochemistry* 2015, 117, 254–266. [CrossRef]
30. Czerwińska, M.E.; Świerczewska, A.; Granica, S. Bioactive constituents of Lamium album L. as inhibitors of cytokine secretion in human neutrophils. *Molecules* 2018, 23, 2770. [CrossRef]

31. Lopez-Castejon, G.; Brough, D. Understanding the mechanism of IL-1β secretion. *Cytokine Growth Factor Rev.* 2011, 201, 189–195. [CrossRef]

32. David, J.M.; Dominguez, C.; Hamilton, D.H.; Palena, C. The IL-8/IL-8R Axis: A double agent in tumor immune resistance. *Vaccines (Basel)* 2016, 4, 22. [CrossRef]

33. Sowa, I.; Zielinska, S.; Sawicki, J.; Bogucka-Kocka, A.; Staniak, M.; Bartusiak-Szczesniak, E.; Podolska-Fajks, M.; Kocjan, R.; Wojciak-Kosior, M. Systematic evaluation of chromatographic parameters for isoquinoline alkaloids on XB-C18 core-shell column using different mobile phase compositions. *J. Anal. Methods Chem.* 2018, 3, 1–8. [CrossRef]

34. Staniak, M.; Wójcik-Kosior, M.; Sowa, I.; Strzemski, M.; Sawicki, J.; Dresler, S.; Tyszczuk-Rotko, K. Applicability of a monolithic column for separation of isoquinoline alkaloids from Chelidonium majus extract. *Molecules* 2019, 24, 3612. [CrossRef] [PubMed]

35. Boyum, A. A one-stage procedure for isolation of granulocytes and lymphocytes from human blood. General sedimentation properties of white blood cells in a 1g gravity field. *Scand. J. Clin. Lab. Invest.* 1968, 97, 51–76.

**Sample Availability:** Samples of the plant extract are available from the authors.